Press Release Summary:
Suited for both localized and systemic therapies, PROLOC(TM) Bioadhesive Drug Delivery System helps deliver drugs locally or systemically from various mucosal absorption sites on body. With capacity for high drug loading, it incorporates USP-grade polysaccharide and polycarboxylated polymer, and is effective as sustained or controlled release preparation with active agent. System is fully erodable, and can be utilized as powder, compressed into tablet, or cast as film.
Original Press Release:
New Bioadhesive for Transmucosal Drug Delivery Introduced by National Adhesives
BRIDGEWATER, NJ, November 8, 2007 - The Transdermal business group of National Adhesives has launched the PROLOC(TM) Bioadhesive Drug Delivery System, a new bioadhesive technology that provides the means to deliver drugs locally or systemically from various mucosal absorption sites on the body. According to National Adhesives officials, several successful clinical trials have been completed to support the delivery of drugs across the mucosa using this novel technology. These clinical trials include successful delivery via buccal, vaginal, ocular and nasal absorption sites.
PROLOC is a proprietary technology providing superior bioadhesive properties with the capacity for high drug loading. The proprietary process, which does not create a new chemical entity, incorporates a USP-grade polysaccharide and polycarboxylated polymer and is effective as a sustained or controlled release preparation with an active agent. The system is fully erodable and can be utilized as a powder, compressed into a tablet or cast as a film.
PROLOC is effective for both localized and systemic therapies. PROLOC facilitates transmucosal drug delivery providing a convenient means for rapid and direct local or systemic absorption and onset of therapeutic effects, allowing lower dosages and resulting in fewer side effects.
"We are very pleased that our first licensing agreement incorporating the PROLOC technology, a buccal application, is a commercial success. Additionally we have a number of projects under way focused on delivery through various absorption sites. PROLOC is quickly being recognized as a means to enable line extensions, extension of patent protection, repositioning of existing products and of course as a means to develop new products for existing compounds," said Michael Trisch, Global Business Manager for National's Transdermal Adhesives group. "We are very excited about the future of PROLOC and its differentiated features. The PROLOC bioadhesive technology has the potential to expand or to open up new opportunities for transmucosal and other unique delivery therapies."
More information is available by contacting
Michael Trisch at 908-685-5317 (business inquiries)
Susan Lydzinski, 908-685-5462
or Dr. Paul Foreman, 908-685-5456 (technical inquiries)
or by email to PROLOC@nstarch.com.
National Adhesives has been an integral part of the bioadhesive market since the technology's inception. As the global leader in acrylic polymers for transdermal drug delivery, National's DURO-TAK® pressure sensitive adhesives are approved in over 40 unique commercial patches marketed in the Americas, Australia, China, Europe, India, Japan and Korea. National Adhesives has more than 35 years of experience and expertise in acrylic pressure sensitive adhesives, technical service, regulatory support, and manufacturing capability in both North America and Europe.
National Adhesives is a unit of National Starch and Chemical Company, which had worldwide sales of $3.7 billion in 2006. National Adhesives offers hot melt, liquid emulsion and solvent-borne solution adhesives to customers worldwide. National Adhesives' products are based on polyurethane, acrylic, rubber, ethylene vinyl acetate, epoxy, polyvinyl acetate and starch and dextrin chemistries. National has its headquarters in Bridgewater, NJ, and is a member of the ICI Group.